Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors

Ard van Veelen, Shahab Abtahi, Patrick Souverein, Johanna H M Driessen, Olaf H Klungel, Anne-Marie C Dingemans, Robin van Geel, Frank de Vries, Sander Croes*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Web of Science)


INTRODUCTION: In- and exclusion criteria of randomized clinical trials (RCTs) aim to include a homogeneous study-population. This study compared characteristics of lung cancer patients from phase III RCTs evaluating tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors (ICIs) with characteristics of lung cancer patients in a real world setting in the United Kingdom.

METHODS: A retrospective study was conducted using the Clinical Practice Research Datalink GOLD. Patients (N = 9239) with a first ever lung cancer registration between 2014 and 2018 were identified. Eligibility for inclusion was assessed for twelve RCTs (evaluating TKIs or ICIs). Reasons for potential exclusion and the number of unmet criteria were assessed for each RCT independently. OS was assessed using Kaplan-Meier and Cox proportional hazards analyses.

RESULTS: The proportion of potentially eligible patients was 74.3% and 51.9% for TKI and ICI RCTs, respectively. History of another malignancy, renal insufficiency or concomitant drug-use were main reasons for exclusion. OS was considerably longer for potentially eligible patients. Hazards ratios varied from 1.17 (95% confidence interval, 1.11-1.24) to 1.35 (1.20-1.42) across the RCTs.

CONCLUSION: This study showed that a considerable proportion of lung cancer patients in a real-world setting would have been ineligible for participation in phase III RCTs and that potentially ineligible patients experienced a shorter OS.

Original languageEnglish
Article number102149
Number of pages8
JournalCancer Epidemiology
Early online date13 Apr 2022
Publication statusPublished - Jun 2022


  • CPRD
  • Immune checkpoint inhibitors
  • Lung cancer
  • Study eligibility
  • Tyrosine kinase inhibitors

Cite this